At a Glance
| Peptide | Primary Healing Target | Evidence Grade | Typical Route |
|---|---|---|---|
| BPC-157 | Tendon, ligament, gut mucosa | B (animal + clinical series) | SC injection or oral |
| TB-500 (Tβ4) | Skeletal muscle, fascia, cardiac | B (animal + phase I/II) | SC injection |
| GHK-Cu | Skin, collagen matrix, nerve | B (in vitro + clinical) | Topical or SC |
| KPV | Intestinal epithelium, skin | B (preclinical + IBD trials) | Oral or topical |
| Thymosin Alpha-1 | Immune-mediated repair | A in infectious contexts | SC injection |
| CJC-1295 + Ipamorelin | Systemic recovery via GH pulse | B | SC injection |
Evidence grades reflect available human data and translational consistency. Grade A = RCT-level; Grade B = animal + clinical series or phase I/II.
The question I hear most often in my clinic — from athletes recovering from tendon injuries, from post-surgical patients, from people dealing with chronic gut ulceration — is some version of: “Is there a peptide for this?”
The honest answer is nuanced. Several peptides genuinely accelerate tissue repair through mechanisms that are well-characterised at the molecular level. But they are not interchangeable. Each operates on a different receptor system, targets a different tissue type, and carries a different risk-benefit profile. Recommending “peptides for healing” as a category is like recommending “antibiotics for infection” — directionally correct but clinically useless without specificity.
This guide ranks the most evidence-supported healing peptides from my clinical perspective, explains the mechanism behind each, and gives you the framework to understand which applies to your situation — or your patient’s.
1. BPC-157: The Versatile Front-Runner
Body Protection Compound-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has accumulated more translational animal data than almost any other healing peptide, spanning tendon repair, ligament reconstruction, gut mucosal healing, and even peripheral nerve regeneration.
Why It Works
BPC-157 stabilises nitric oxide (NO) signalling and modulates the VEGF pathway, which drives angiogenesis — the formation of new blood vessels essential to any tissue repair cascade. It also upregulates growth hormone receptor expression in tendon fibroblasts, which explains its consistent effect on connective tissue in animal models. Importantly, it appears to work even under NSAID inhibition, which disrupts COX-pathway-dependent healing and is a significant clinical limitation for conventionally-managed injuries.
Clinical Profile
In the context of musculoskeletal injuries — Achilles tendon tears, ACL recovery, rotator cuff strains — BPC-157 is the peptide I reach for first. For gut conditions including IBD, post-surgical anastomoses, and chemotherapy-induced mucositis, it has shown compelling preclinical results and forms a cornerstone of integrative gut healing protocols.
Dosing context: 250–500 mcg once or twice daily. Oral administration is effective for gut targets; subcutaneous injection is preferred for musculoskeletal applications. Cycles of 8–12 weeks are typical in clinical practice, though no formal human RCTs have established optimal duration.
Caution: BPC-157 is not FDA-approved and operates in a regulatory grey zone in most jurisdictions. Its commercial status has been contested. Sourcing purity and sterility matter enormously for injectable use.
2. TB-500 (Thymosin Beta-4): Muscle, Fascia, and Beyond
Thymosin Beta-4 — often sold as the synthetic fragment TB-500 — is a naturally occurring 43-amino-acid peptide with extraordinarily broad tissue distribution. It was first studied in cardiac healing after myocardial infarction, where it demonstrated angiogenic, anti-fibrotic, and cardiomyocyte-protective effects.
Why It Works
TB-500 promotes actin polymerisation, a fundamental step in cell migration — which is essential for fibroblasts and endothelial cells to populate an injury site. It up-regulates metalloproteinases (MMPs) that remodel scar tissue, reducing the risk of excessive fibrosis. It also modulates inflammatory signalling, shortening the inflammatory phase of healing without eliminating the immune response entirely.
Clinical Profile
Where BPC-157 excels in connective tissue and gut, TB-500 is my preference for skeletal muscle tears, fascial injuries, and cases where I am concerned about fibrotic remodelling — such as post-surgical adhesions or repetitive strain injuries. The two peptides are commonly stacked because their mechanisms are largely complementary rather than redundant.
Dosing context: 2–2.5 mg twice weekly for 4–6 weeks (loading phase), followed by 1–1.25 mg weekly (maintenance). Always subcutaneous. The half-life is short; frequent dosing maintains tissue concentrations.
Note on cardiac use: Human phase I/II trials have been conducted for TB-500 in ischaemic heart disease (PB1046 formulation). These remain exploratory. I do not use TB-500 for cardiac indications outside of research settings.
3. GHK-Cu: Collagen, Skin, and Neuroprotection
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide found in human plasma, urine, and saliva. Its concentrations decline sharply with age — from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60 — a trajectory that correlates broadly with declining tissue repair capacity.
Why It Works
GHK-Cu is a potent activator of collagen, elastin, and glycosaminoglycan synthesis in fibroblasts. It resets gene expression in aged and damaged tissues toward a more youthful repair phenotype — a property documented in a widely cited analysis of human gene expression that showed GHK-Cu modulating over 4,000 genes involved in anti-inflammatory, anti-fibrotic, and tissue repair functions.
It also acts as a superoxide dismutase (SOD) mimetic via its copper complex, reducing oxidative damage in the wound microenvironment.
Clinical Profile
GHK-Cu is the peptide I prioritise for skin-related healing: post-procedural wound repair, chronic venous ulcers, radiation dermatitis, and age-related collagen thinning. It also has documented peripheral nerve protective effects that make it useful post-surgically in cases involving nerve trauma.
Dosing context: Topical: 2–5% formulations applied to wound or skin twice daily. Subcutaneous: 1–2 mg daily for systemic applications. The topical route has the most documented safety data; injection protocols vary widely between practitioners.
4. KPV: The Gut Mucosal Specialist
KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal region of alpha-Melanocyte Stimulating Hormone (α-MSH). It is the most gut-specific of the major healing peptides, exerting potent anti-inflammatory effects at the intestinal epithelial level via direct NF-κB inhibition in enterocytes.
Why It Works
KPV’s mechanism centres on down-regulating the classical inflammatory pathway (IκBα / NF-κB) in intestinal epithelial cells and macrophages. Unlike systemic anti-inflammatory agents, KPV achieves this locally at the gut mucosa, minimising systemic immunosuppression. It also promotes epithelial barrier restoration — specifically tight junction protein expression — which is mechanistically central to leaky gut syndrome and IBD pathology.
Clinical Profile
In my practice, KPV is a cornerstone of gut healing protocols for patients with IBD, post-infectious enteritis, SIBO-associated mucosal damage, and post-antibiotic dysbiosis. Early clinical trials in ulcerative colitis (orally delivered KPV nanoparticles) demonstrated meaningful improvements in histological inflammation scores.
Dosing context: Oral, 500 mcg–1 mg twice daily with food. Oral delivery is effective because KPV retains bioactivity in the gut lumen. Unlike BPC-157, there is no particular advantage to injection for gut-targeted KPV use.
Stack note: KPV and BPC-157 are frequently combined in gut healing protocols. Their mechanisms are complementary — KPV suppresses inflammation while BPC-157 drives mucosal repair.
5. Thymosin Alpha-1: Immune-Mediated Repair
Thymosin Alpha-1 (Tα1) occupies a distinct position among healing peptides because its primary target is the immune system, not the structural tissue. It is a 28-amino-acid peptide produced naturally by the thymus gland that drives dendritic cell maturation, NK cell activation, and Treg balance.
Why It Works
In the context of healing, Thymosin Alpha-1’s relevance is greatest when immune dysfunction is impeding repair — chronic infection, immune exhaustion post-surgery, cancer-related immunosuppression, or the immune dysfunction seen in long COVID and chronic Lyme disease. It re-establishes the immune surveillance capacity that normal wound resolution requires, including clearance of senescent cells and biofilm-associated bacteria in chronic wounds.
Thymosin Alpha-1 is approved in many countries (under the brand name Zadaxin) for hepatitis B, hepatitis C, and malignancy — making it the most clinically validated peptide on this list.
Dosing context: 1.6 mg subcutaneously, twice weekly for 4–6 weeks. The schedule mirrors established immunology protocols. Duration is condition-dependent.
Clinical context: I use Tα1 most often in chronic wound patients with concurrent immune compromise — post-chemotherapy, chronic Lyme, or persistent viral infections. It is not my first choice for acute musculoskeletal healing in otherwise immunocompetent patients.
6. CJC-1295 + Ipamorelin: Systemic Recovery via GH Optimisation
This peptide combination does not repair tissue directly. Instead, it augments endogenous growth hormone pulsatility, which accelerates every downstream repair process: protein synthesis, IGF-1 signalling, lipolysis, sleep architecture, and collagen turnover.
For patients where systemic repair capacity is blunted — relative GH deficiency in middle age, post-surgical catabolic states, or intensive athletic training loads — optimising the GH axis creates a physiological environment more conducive to repair.
Dosing context: CJC-1295 without DAC (100 mcg) + Ipamorelin (100–200 mcg) subcutaneously at bedtime, 5 nights per week. The bedtime timing aligns with the natural nocturnal GH peak and maximises synergy with deep sleep.
Note: This combination is systemic and affects multiple systems. It is not a substitute for targeted tissue-repair peptides but functions as a valuable adjunct in structured healing protocols.
How I Choose in Clinical Practice
The decision framework I use:
For acute musculoskeletal injury (tendon, ligament, muscle): BPC-157 + TB-500 combination, subcutaneous. Add CJC-1295/Ipamorelin if the patient is over 40 or systemically deconditioned.
For chronic gut pathology (IBD, leaky gut, post-infectious): KPV oral + BPC-157 oral, often with concurrent microbiome support.
For skin wound healing (post-surgical, ulcers, radiation injury): GHK-Cu topical as primary, +/- BPC-157 SC for deep tissue involvement.
For immune-compromised healing: Thymosin Alpha-1 SC to restore immune scaffolding, then layer tissue-specific peptides.
For systemic recovery optimisation: CJC-1295 + Ipamorelin, particularly in athletes and post-surgical patients.
The evidence base for all of these is substantial in preclinical models but still developing in human RCTs. I prescribe them in the context of thorough clinical assessment, informed consent, and pharmaceutical-grade sourcing — not as over-the-counter supplements.
Related Articles
- BPC-157: Mechanisms, Dosage, and Clinical Evidence — Deep dive into the most widely studied healing peptide.
- TB-500 Dosage Guide: Protocols for Tendon and Muscle Repair — Detailed TB-500 dosing and cycling strategies.
- GHK-Cu: Copper Peptide for Skin, Collagen, and Neuroprotection — The science behind the copper peptide that declines with age.
- Peptides for Women: Hormonal Considerations and Tissue Repair — Gender-specific adaptations to healing peptide protocols.
- Gut Healing Peptides: BPC-157, KPV, and the Gut Repair Protocol — How peptides restore intestinal mucosal integrity.
References
- Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27040287
- Smart N, et al. “Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization.” Nature. 2007;445(7124):177-182. PMID: 17108969
- Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
- Dou X, et al. “KPV, a tripeptide derived from POMC, shows anti-inflammatory activity in a murine colitis model.” Biochem Pharmacol. 2019;163:423-431. PMID: 30802440
- Romani L, et al. “Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis.” Nat Med. 2010;16(5):529-535. PMID: 20418886
- Andersen LL, et al. “Growth hormone-releasing peptides and healing: an overview.” Peptides. 2020;126:170249. PMID: 32014489
- Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol. 2011;110(3):774-780. PMID: 21030672